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Abstract  
Rationale: Sex hormones play a role in pulmonary arterial hypertension (PAH), but the 
menstrual cycle has never been studied. 
Objectives: We conducted a prospective observational study of eight women with stable PAH 
and 20 healthy controls over one cycle. 
Methods: Participants completed four study visits one week apart starting on the first day of 
menstruation. Relationships between sex hormones, hormone metabolites, and extracellular 
vesicle microRNA (miRNA) expression and clinical markers were compared with generalized 
linear mixed modeling.
Results: Women with PAH had higher but less variable estradiol (E2) levels (p < 0.001) that 
tracked with six-minute walk distance (6MWD) (p < 0.001), N-terminal prohormone of brain 
natriuretic peptide (NT-proBNP) (p = 0.03) levels, and tricuspid annular plane systolic excursion 
(p < 0.01); the direction of these associations depended on menstrual phase. 
Dehydroepiandrosterone-sulfate (DHEA-S) levels were lower in women with PAH (all visits, p < 
0.001). In PAH, each 100 g/dL increase in DHEA-S was associated with a 127-meter increase in 
6MWD (p < 0.001) and was moderated by the cardioprotective E2 metabolite 2-
methoxyestrone (p < 0.001). As DHEA-S increased, NT-proBNP levels decreased (p = 0.001). 
Expression of extracellular vesicle miRNAs-21, -29c, and -376a was higher in PAH, moderated by 
E2 and DHEA-S levels, and tracked with hormone associated changes in clinical measures. 
Conclusions: Women with PAH have fluctuations in cardiopulmonary function during 
menstruation driven by E2 and DHEA-S. These hormones in turn influence transcription of 
extracellular vesicle miRNAs implicated in the pathobiology of pulmonary vascular disease and 
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cancer.  
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Pulmonary arterial hypertension (PAH) was first described in pre-menopausal women (1). 
Anecdotally, PAH can be unmasked or exacerbated by oral contraceptive pills (OCP) and 
pregnancy (2). In men and post-menopausal women, higher estradiol (E2) and lower 
dehydroepiandrosterone-sulfate (DHEA-S) levels are associated with the risk and severity of 
PAH (3-5). No studies have accounted for cyclical hormonal changes with menstruation in pre-
menopausal women with PAH. The menstrual cycle has not been leveraged to provide 
mechanistic insight into how sex hormones contribute to PAH pathogenesis.
In healthy women and women with asthma (also characterized by a female sex bias), 
diffusing capacity (DLCO) varies over the menstrual cycle but the mechanisms that govern these 
fluctuations may differ in health versus disease (6-8). Hormonal variation in pre- and post-
menopausal women is associated with increased vascular endothelial growth factor (VEGF) 
levels and extracellular vesicle (EV) formation (6, 9-11). We have shown that EVs can prevent 
and reverse experimental pulmonary hypertension and that there is a miRNA signature of 
exosomes in human PAH that promotes vascular proliferation (12, 13). E2 increases circulation 
of hematopoietic progenitors leading to microvessel growth in the heart and lungs (14-17). The 
pro-inflammatory E2 metabolite 16-hydroxyestrone (16-OHE1) as compared to the 2-
compounds (2-methoxyestrone [2-ME] and 2-methoxyestradiol) has been linked to cancer 
angioinvasion and PAH (18-20). A pilot study of the E2 receptor modulator fulvestrant reduced 
circulating hematopoietic progenitors and 16-hydoxyestradiol in post-menopausal women (21). 
Finally, DHEA reduces oxidative stress, is required for nitric oxide (NO) synthesis and has a 
number of purported cardiopulmonary benefits (3, 22, 23). Whether low DHEA-S levels occur in 
pre-menopausal women and vary with the menstrual cycle in PAH is unknown. As there are on-
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going clinical trials manipulating E2 and DHEA in pre-menopausal women with PAH 
(NCT03528902; NCT03648385), it is critical to address these gaps in knowledge.
We sought to understand the relationship between cyclic sex hormone and metabolite 
changes and cardiopulmonary function in women with PAH as compared to healthy controls 
over one menstrual cycle. We hypothesized that: 1) hormone levels (specifically higher E2 and 
lower DHEA-S levels) and menstrual cycle phase would be associated with decrements in 
measures of cardiopulmonary function, 2) the impact of E2 and DHEA-S and menstrual phase 
on these measures would be greater in PAH, and 3) relationships between hormone levels and 
clinical end points would be moderated by E2 metabolites. We also explored the relationship 
between hormone fluctuation and miRNA expression from circulating EVs in PAH as compared 
to controls; we focused on miRNAs implicated in angioinvasion in cancer or in PAH in an effort 
to gain mechanistic insight into hormone-driven effects on heart-lung function. 
Methods  
Study Design 
We performed a prospective longitudinal study of pre-menopausal women with PAH as 
compared to healthy controls during one menstrual cycle. Participants were assessed on a 
weekly basis for four visits with the first day of week one defined as day one of menstruation. 
Participants called study staff on the first day of menstruation and study visits were arranged 
within 48 hours and then at fixed weekly intervals thereafter. Patients with PAH were enrolled 
from the Rhode Island Hospital Pulmonary Hypertension Center. Controls were recruited from 
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the Women’s Medicine Collaborative of the Lifespan Hospital system, a center focused on the 
medical needs of healthy women, as well as hospital staff and local advertisements. This study 
was approved by the Lifespan Institutional Review Board (IRB #024112) and informed consent 
was obtained from all participants. 
Study Sample
Case definition. We included menstruating women with World Symposium Group 1 PAH. 
Traditional hemodynamic criteria (24) were required as well as prior pulmonary testing 
(pulmonary function testing, chest computed tomography, and ventilation/perfusion scans) 
excluding concurrent chronic lung disease and chronic thromboembolic disease. Patients on 
targeted PAH therapy were enrolled provided they had at least four weeks of stability (no 
hospitalizations, new PAH therapy, or PAH medication adjustments). Patients who had acute 
issues arise during the study period discontinued subsequent visits and were invited to repeat 
the entire study protocol once they were clinically stable.
Control definition. Women with a history of ≥12 months of regular menstrual cycles and 
no prior history of chronic heart or lung disease were eligible for screening. Participants were 
enrolled if they denied subjective cardiopulmonary symptoms and had normal screening 
spirometry. 
Enrollment was coterminous for PAH cases and controls and therefore not matched. 
Women less than 18 years old or who were pregnant or breastfeeding were excluded. OCP use 
was not an absolute exclusion criterion.
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Clinical Variables 
Participant demographics, anthropometrics, smoking, medication, and obstetric/gynecologic 
history was collected at enrollment.
Peripheral Blood Markers and Study Assessments
Sex hormone levels, E2 metabolites, and angiogenesis markers (VEGF-receptor 2 [VEGF-R2], 
angiopoietin-2 [Ang-2], and EVs) were measured from peripheral blood as detailed in the online 
data supplement. Investigators and study personnel involved in their measurement were 
blinded to case-control status, the temporal order of samples and timepoint in menstrual cycle. 
Values of all bioassays above or below the lower limit of detection were assigned a value of the 
upper or lower detection limit respectively. Markers of cardiopulmonary function including six-
minute walk distance (6MWD), DLCO, N-terminal prohormone of brain natriuretic peptide (NT-
proBNP) levels and tricuspid annular plane systolic excursion (TAPSE) from echocardiograms (in 
PAH cases only) were measured weekly using standardized methods with study staff and 
investigators blinded to case-control status (except for TAPSE) and visit timing (see online data 
supplement).
Statistical Analysis 
All analyses were conducted using SAS Software 9.4 (SAS Inc. Cary, NC). Summary data are 
presented as median and first and third quartiles and categorical data as frequency with 
percentage. Sex hormones (E2, DHEA-S), their metabolites (2-ME), and NT-proBNP were natural 
log-transformed. Outcomes of interest (6MWD, DLCO, NT-proBNP, TAPSE) were modeled as a 
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function of sex hormone (E2, DHEA-S) and/or metabolite (2-ME) over time (menstrual cycle, 4 
timepoints) between women with PAH and controls (three-way and four-way interactions) 
using generalized linear mixed modeled with sandwich estimation assuming normal or 
lognormal distributions (where appropriate) with the GLIMMIX procedure. All interval 
estimates were calculated for 95% confidence. Alpha was established at the 0.05 level.
Results 
A total of eight women with PAH were enrolled. Three participants had clinical events unrelated 
to their PAH or personal logistical issues arise over the course of the study protocol and initially 
did not complete all study visits. They were re-enrolled after these issues resolved, clinical 
stability and enrollment criteria were re-confirmed, and completed all study visits over one 
menstrual cycle. In these participants, all data for available visits were analyzed and nested 
within subject. Twenty controls were enrolled and all completed the study protocol during one 
menstrual cycle. Women with PAH tended to be slightly older and more diverse with higher 
body mass index, were more likely to be smokers, and to have irregular menstrual periods by 
self-report as compared to controls. Only one control participant was taking OCPs. Among 
women with PAH, idiopathic PAH was the most common subtype (38%) and, as was required 
for study enrollment, participants were well-controlled on PAH therapy (63% were functional 
class II; 75% were on combination therapy) (Table 1). 
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Hormone Fluctuations during the Menstrual Cycle
Changes in hormone levels over the course of one cycle (four study visits) are depicted in Figure 
1 and Table 2. Women with PAH tended to have much lower variability in E2 levels as compared 
to controls over the cycle (i.e., controls had wider confidence intervals despite having twice the 
sample size). Levels of E2 were higher for PAH cases than controls in the follicular phase (visit 1 
and 2) and at the end of the luteal phase (visit 4) (p < 0.001) (Figure 1A). Levels of DHEA-S were 
lower in PAH cases (red) as compared to controls (blue) throughout the menstrual cycle (all 
visits, p < 0.001)(Figure 1B). 
Estradiol and Markers of Cardiopulmonary Function 
The relationship between E2 and 6MWD was moderated by case-control status and by 
menstrual phase (p < 0.001) (see Figure 2A). Women with PAH had shorter 6MWD and NT-
proBNP levels than controls (as expected) and significant but inverse associations between E2 
and 6MWD, as well as E2 and NT-proBNP respectively over the cycle. For example, each 1 
pg/mL increase in Ln(E2) was associated with a 28-meter decrease in 6MWD in the follicular 
phase (visit 1) and a 34-meter increase in 6MWD in the luteal phase (visit 4) in PAH cases. 
Similarly, as E2 levels increased in the follicular phase (visits 1 and 2), NT-proBNP levels 
increased, but this relationship reversed in the luteal phase (visits 3 and 4) (p = 0.03) (Figure 
2B). There was no evidence of a relationship between E2 and 6MWD nor E2 and NT-proBNP 
over the cycle in controls. There was also a variable relationship between E2 levels and TAPSE in 
PAH cases; as E2 increased, TAPSE fluctuated depending on menstrual cycle and study visit 
(Figure 2C). Results were unchanged when age was included in the models for 6MWD, NT-
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proBNP, and TAPSE. We conducted sensitivity analyses in which we excluded nulliparous 
controls (all PAH women had at least one prior pregnancy); we observed more variability in the 
effect estimates between levels of E2 and end points (6MWT, NT-proBNP) in controls, but the 
interactions with case-control status and study visit, respectively, remained unchanged and 
significant. DLCO was higher for controls than cases (p < 0.001), regardless of E2 level and phase 
(p = 0.23) (data not shown).
Dehydroepiandrosterone-Sulfate and Markers of Cardiopulmonary Function 
The relationship between DHEA-S and 6MWD was moderated by case-control status 
throughout the cycle (p < 0.001) (Figure 3A). Only women with PAH had evidence of longer 
6MWD with increases in DHEA-S levels. Each unit increase in Ln(DHEA-S) was associated with a 
94-meter increase in 6MWD in women with PAH (in a normal distribution without natural log 
transformation, each 100 g/dL increase in DHEA-S was associated with an increase of 127 
meters). This association was consistent across the follicular and luteal phase (i.e., there was no 
evidence of interaction by study visit). Given the time invariant nature of this relationship, the 
main effect (6MWD regressed on DHEA-S) is represented in Figure 3B. There was an inverse 
relationship between DHEA-S levels and NT-proBNP levels such that as DHEA- levels increased, 
NT-proBNP levels decreased, an association which varied by case-control status and visit (p = 
0.001) (Figure 3C). In PAH, as DHEA-S levels increased, TAPSE increased during menstruation, 
the follicular and early luteal phases (visits 1, 2, and 3) (p = 0.003)(Figure 3D). Results were 
unchanged when age was included in the models for 6MWD, NT-proBNP, and TAPSE. Exclusion 
of nulliparous controls and the control subject taking OCPs, respectively, did not change the 
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results. There was no evidence of a relationship between DHEA-S levels and DLCO over the 
course of the study in cases or controls (data not shown). 
Estrogen Metabolites and Markers of Cardiopulmonary Function
There was no evidence of a difference between 2-ME between PAH cases and controls over 
time (all p > 0.60) (Figure E1). Over the course of the cycle, 2-ME increased for both groups (p < 
0.001). There was no evidence of a difference between PAH cases and controls between 2-ME 
levels and 6MWD (p = 0.62), NT-proBNP (p = 0.26), nor DLCO (p = 0.54) over time. In women 
with PAH, as 2-ME increased, the association with TAPSE varied over the cycle (p = 0.001) 
(Figure E2). We measured additional metabolites including 2-methoxyestradiol, 16-OHE1 and 
16-hydroxyestradiol but too many values were below the lower limit of detection in both cases 
and controls, rendering informative analyses impossible (Table 2).
PAH Moderates the Relationship between DHEA-S, 2-ME, and Six-Minute Walk Distance 
There was evidence of significant moderation between case-control status over time by 2-ME 
and DHEA-S levels on 6MWD. As is depicted in the 3-dimensional plots in Figure 4, in women 
with PAH, the relationship between lower levels of Ln(DHEA-S) and shorter 6MWD was 
moderated by lower Ln(2-ME) levels (p < 0.001). This relationship did not exist in controls. 
There was no evidence of moderation in the models for E2 (data not shown).
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Extracellular Vesicle miRNA Expression Varies in PAH Cases versus Controls According to Time 
and Hormone Levels 
Ninety-four miRNAs were significantly expressed in EVs from PAH cases as compared to 
controls; many miRNAs were significantly associated with E2 and DHEA-S in women with PAH 
(data not shown). We focused on three miRNAs previously linked with sex hormone biology and 
the pathobiology of pulmonary vascular disease. Expression of miRNA-21, -29c and -376a were 
increased in PAH cases as compared to controls and had more fluctuation over the course of 
the cycle. Levels of E2 significantly moderated the relationship between miRNA-29c and -376a 
expression, PAH status and menstrual phase respectively (p < 0.001 for both). In women with 
PAH, increasing levels of E2 were associated with decreased miRNA-29c expression in the 
follicular phase (visits 1 and 2) and increased expression in the luteal phase (visits 3 and 4) 
(Figure E3A) – a pattern not observed in controls and similar to that seen between E2 levels and 
clinical measures. Increasing E2 levels were associated with decreased miRNA-376a expression 
in PAH cases but no relationship was observed for controls (Figure E3B). Increasing levels of E2 
were associated with decreased miRNA-21 expression in PAH cases but increased expression in 
controls (p < 0.001), but these relationships did not significantly vary over the menstrual cycle 
(p = 0.22) (Figure E3C). The relationship between miRNA expression, PAH status and menstrual 
phase was significantly moderated by DHEA-S levels for miRNA-29c (p < 0.001), miRNA-376a (p 
= 0.001) and possibly miRNA-21 (p = 0.06). For example, increasing levels of DHEA-S were 
associated with increasing expression of miRNA-29c and -376a over the course of the cycle in 
PAH cases whereas the relationships in controls tended to be static or reversed (Fig E4A and B). 
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The DHEA-S-associated fold increases in miRNA-29c and -376a expression tracked with longer 
6MWD and higher TAPSE in women with PAH. 
Additional Hormones and Angiogenesis Markers of Interest
Other hormones known to fluctuate during the menstrual cycle (luteinizing hormone [LH], 
progesterone) failed to have significant associations with end points or moderators of interest 
in PAH participants that were distinguishable from controls (data not shown). While there were 
some significant associations detected between E2 and DHEA-S levels, VEGF-R2 and Ang-2 
levels, and cardiopulmonary measures in PAH cases as compared to controls, no consistent 
signals emerged (data not shown).
Discussion 
Pre-menopausal women with PAH have significant fluctuations in markers of cardiopulmonary 
function (6MWD, NT-proBNP, TAPSE) over the course of the menstrual cycle that may be driven 
by E2 and DHEA-S and are distinct from controls. In women with PAH, E2 levels tended be 
higher and vary less as compared to controls and have variable, inverse relationships with 
clinical end points that depended on menstrual cycle timing. As in men and post-menopausal 
women, levels of DHEA-S were lower in premenopausal women as compared to controls and – 
unlike E2 – had consistent, robust associations with clinical measures such that lower levels 
were associated with worse clinical measures of PAH across the cycle. The cardioprotective E2 
metabolite 2-ME moderated the relationship between DHEA-S and 6MWD, but not E2 and 
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cardiopulmonary outcomes in women with PAH. Women with PAH tended to have higher 
expression of EV miRNAs-21, -29c, and -376a which were moderated by E2 and DHEA-S levels 
and tracked with sex hormone associated changes in clinical measures. This is the first study to 
characterize the menstrual cycle in women with PAH, to document cyclical fluctuations in PAH 
clinical metrics that are associated with major hormones of biological import, and to identify 
potential mechanistic mediators in the relationship between sex hormones and PAH disease 
activity. 
While we and others have previously linked higher circulating E2 levels to the risk and 
severity of PAH in both men and post-menopausal women (3-5), these relationships have not 
been robustly studied in young women who are still menstruating. In a brief journal 
correspondence, Yuan et al. described lower levels of circulating E2 as compared to age-
matched controls in pre-menopausal women with incident idiopathic PAH in the follicular phase 
of menstruation (25). In our study, the tendency for E2 to be higher but less variable (also 
observed in the Yuan study) in PAH women mirrors our prior observations that post-
menopausal women with PAH treated with the aromatase inhibitor anastrozole had lesser 
reductions in circulating E2 as compared to anastrozole treated women with breast cancer (26). 
Elevated E2 levels may therefore be a hallmark of the PAH disease process itself. 
The question of whether E2 is beneficial or harmful has been the subject of intense 
debate in human and experimental studies and has been dubbed the “estrogen paradox” and 
the “estrogen puzzle” of PAH (27, 28). Our data confirm this conundrum and suggests 
pleiotropism as higher E2 levels were associated with “better” and “worse" end points 
depending on menstrual cycle phase. This observation suggests that clinical trials targeted at 
Page 15 of 44
 ANNALSATS Articles in Press. Published September 04, 2020 as 10.1513/AnnalsATS.202006-671OC 
 Copyright © 2020 by the American Thoracic Society 
estrogen signaling should include comprehensive and right ventricle (RV)-specific end points 
over a sufficient duration. The randomized clinical trial of anastrozole in PAH (PHANTOM; 
NCT03229499) does not include pre-menopausal women. In our on-going trial of DHEA in PAH 
(Effects of Dehydroepiandrosterone in Pulmonary Hypertension [EDIPHY]; NCT03648385) which 
includes pre-menopausal women, menstrual cycle-related variability should be minimized by 
the crossover design, a consistent number of cycles in each 18-week treatment period, and the 
measurement of all sex hormones and their metabolites at each study visit.
Estrogen metabolites have dimorphic and tissue specific effects and have been linked to 
cancer, cardiovascular health, and PAH. In a cohort of heritable PAH patients with two 
premenopausal women, lower ratios of 2 /16 E2 metabolites were reported (19). This is 
somewhat consistent with our findings that lower 2-ME levels moderated the relationship 
between lower DHEA-S levels (but surprisingly not E2 levels) and shorter 6MWD. The active 
metabolite 2-methoxyestradiol has been implicated in experimental models of PAH (29-31) and 
of the 2-compounds, 2-ME is relatively inactive. While not directly measured, lower levels of 
DHEA-S in PAH may modulate catechol-O-methyltransferase (COMT) and lead to lower levels of 
2-ME; COMT metabolizes the 2-compounds and has been speculated to modify breast cancer 
risk (32).  We were unable to detect signals with 2-methoxyestradiol (the active metabolite), 
16-OHE1 and 16-hydroxyestradiol levels because of a floor effect in both cases and controls. 
Recently, 16-OHE1 and 16-hydroxyestradiol levels were reported to be altered in a cohort of 
men and post-menopausal women (mean age for both sexes 57 years) with idiopathic PAH as 
compared to controls (33). The fact that E2 and its metabolites have now been shown in a 
number of studies to differ between PAH patients and controls (despite critical differences in 
Page 16 of 44
 ANNALSATS Articles in Press. Published September 04, 2020 as 10.1513/AnnalsATS.202006-671OC 
 Copyright © 2020 by the American Thoracic Society 
study populations such as age, menopausal status and PAH sub-type) also points to a critical 
role for E2 in PAH pathogenesis. 
The robust associations between DHEA-S levels in PAH patients (but not controls) and 
clinical end points were largely independent of time and were directionally consistent. While it 
is possible that the relationship between DHEA-S levels and 6MWD in women with PAH is in-part 
explained by effects on the systemic musculature, this is unlikely to explain the associations with 
TAPSE and NT-proBNP levels. Our prior work demonstrated associations between lower DHEA-S 
levels and worse hemodynamics (right atrial pressure and pulmonary vascular resistance) in both 
sexes and mortality in post-menopausal women (3, 5). Low levels of DHEA-S and its metabolites 
were associated with mortality in an unbiased metabolomics analysis in PAH patients (23). 
DHEA binds to an endothelial cell-surface receptor coupled to NO synthase and regulates 
endothelin-1 production (34, 35), two major treatment targets in the PAH causal pathway. 
Human pulmonary artery endothelial cells actively metabolize DHEA and treatment of these cells 
from PAH patients decreases STAT3 activation (36). In multiple experimental models of PAH, 
DHEA prevents and rescues pulmonary vascular and RV dysfunction (22). Together with the 
current findings, this provides a strong rationale for our ongoing clinical trial of DHEA in patients 
with PAH.
Levels of E2 and DHEA-S in PAH cases but not controls modulated the expression of 
miRNA-21, -29c, and -376a in circulating EVs and mirrored sex hormone-based associations 
with clinical markers. These miRNAs have been implicated in the pathobiology of PAH, vascular 
ischemic injury, and cancer (37-42). This observation, along with the greater variability in 
miRNA expression over the cycle in PAH cases as compared to controls, suggests that E2 and 
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DHEA-S stimulate hematopoietic signals and transcription of EV miRNA cargo to influence 
vascular and cardiopulmonary homeostasis in PAH. Higher E2 levels were associated with lower 
miRNA-21 expression in women with PAH whereas controls demonstrated the inverse 
relationship throughout the cycle. miRNA-21 has been identified as a central regulator of bone 
morphogenetic protein and Rho-associated kinase signaling, moderating angiogenesis and 
vascular tone in PAH (37). Increasing levels of DHEA-S and E2 (in the luteal phase only) were 
associated with greater expression of EV miRNA-29c. Expression of miRNA-376a correlated 
directly with DHEA but inversely with E2 levels. In Bmpr2 mutant mice, 16α-OHE1 leads to 
upregulation of miR-29, which plays a key role in cellular energetics and metabolism (38, 43). 
The family of miRs that includes miR-376a have anti-proliferative and anti-migratory effects on 
tumor cells and down-regulate cyclin-dependent kinases, an emerging therapeutic target in 
PAH (44-46). Whether these observations have a bearing on E2 and DHEA modulation as a 
treatment strategy in PAH is impossible to conclude given the potential for dynamic feedback 
over the cycle in menstruating women. 
Our study has limitations. Our “time zero” for the protocol was the first day of 
menstruation. We did not confirm ovulation by LH surge or temperature change in real time. 
We required clinical stability without changes in PAH medications prior to study enrollment in 
order to minimize the risk of bias and confounding. The scope of inference for our conclusions 
therefore applies only to PAH patients with stable and treated disease. The study is 
underpowered to detect differences among women with PAH on different treatment regimens 
and most (75%) were on combination PAH therapy. We did not measure activity levels or 
environmental or dietary exposures which may have differed between women with PAH and 
Page 18 of 44
 ANNALSATS Articles in Press. Published September 04, 2020 as 10.1513/AnnalsATS.202006-671OC 
 Copyright © 2020 by the American Thoracic Society 
healthy controls. Weekly echo-based measurements of RV function were not performed in 
controls as these were unlikely to be informative and likely too insensitive (or imprecise) to 
detect subtle week-to-week changes in RV function in health and perhaps also treated/stable 
PAH. Our analyses do not account for a potential “lag” effect between hormone, metabolites, 
miRNAs and end points – the potential for time-based interactions are limitless and we are 
restricted by sample size. 
Conclusions
This is the first study to leverage the menstrual cycle in PAH. Women with PAH had unique and 
dynamic associations between circulating E2 and DHEA-S, menstrual phase, and 
cardiopulmonary function as compared to healthy controls. E2 and DHEA-S driven associations 
with heart-lung function were moderated by E2 metabolites and tracked with altered EV miRNA 
transcription in PAH women, suggesting a critical role for these hormones in PAH pathogenesis. 
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Figure Legends:
Figure 1. Hormone fluctuations over the course of the menstrual cycle. Panel A) Mean 
Ln(estradiol) levels over the menstrual cycle (visit 1, 2, 3, and 4) between pulmonary arterial 
hypertension cases (red) and controls (blue) with 95% confidence intervals. Panel B) Mean 
Ln(DHEA-S) levels over the menstrual cycle (visit 1, 2, 3, and 4) between pulmonary arterial 
hypertension cases (red) and controls (blue) with 95% confidence intervals. DHEA-
S=dehydroepiandrosterone-sulfate.
Figure 2. Estradiol levels during the menstrual cycle (visit 1, 2, 3, and 4) and the relationship to 
clinical end points in pulmonary arterial hypertension cases (red) and controls (blue) with 95% 
confidence bands. Panel A) Six-minute walk distance (6MWD), meters (m). Panel B) N-terminal 
prohormone of brain natriuretic peptide levels (NT-proBNP), Ln(pg/mL). Panel C) Tricuspid 
annular plane systolic excursion (TAPSE), Ln(centimeters)(cm) in pulmonary arterial 
hypertension cases only.
Figure 3. Dehydroepiandrosterone-sulfate (DHEA-S) levels and the relationship to clinical end 
points in pulmonary arterial hypertension cases (red) and controls (blue) with 95% confidence 
bands. Panel A) DHEA-S levels during the menstrual cycle (visit 1, 2, 3, and 4) and the 
relationship to six-minute walk distance (6MWD), meters (m). Panel B) Overall relationship 
between DHEA-S and 6MWD, all visits. Panel C) N-terminal prohormone of brain natriuretic 
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peptide levels (NT-proBNP), Ln(pg/mL). Panel D) Tricuspid annular plane systolic excursion 
(TAPSE), Ln(centimeters)(cm) in pulmonary arterial hypertension cases only.
Figure 4. Relationship between six-minute walk distance (6MWD) by 
Ln(dehydroepiandrosterone-sulfate) (DHEA-S) levels and Ln(2-methoxyestrone) (2-ME) levels in 
pulmonary arterial hypertension (PAH) cases (red cross) and controls (blue pyramids) over time 
(visits 1,2,3,4); 180O rotation is provided for interpretation.   
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Table 1. Subject characteristics 
Variables PAH Cases Controls
Number 8 20
Age, yr 37 (31, 42) 28 (24, 40)
Race, n (%)
White 5 (63) 15 (75)
Black 1 (13) 3 (15)
Asian 0 (0) 1 (5)
American Indian or Alaska Native 0 (0) 0 (0)
Native Hawaiian or Other Pacific Islander 0 (0) 0 (0)
Other 2 (25) 1 (5)
Ethnicity, n(%)
Hispanic 2 (25) 1 (5)
Not Hispanic 6 (75) 19 (95)
BMI, kg/m2 30 (28, 31) 25 (20, 32)
Current smoker, n (%) 3 (38) 0 (0)
Ever-smoker, n(%) 5 (63) 2 (10)
Pack years among ever-smokers 4 (1, 15) 5 (3, 8)
Hormonal factors
Current oral contraceptive pill use, n (%) 0 (0) 1 (5)
Age at menarche 13 (12, 13) 13 (13, 13)
Regular menstrual periods, n (%) 5 (63) 19 (95)
Irregular menstrual periods, n(%) 3 (38) 1 (5)
Number of pregnancies 3 (2, 3) 0 (0, 2)
Number of live births 2 (1, 2) 0 (0, 2)
Surgical removal of ovaries or uterus 0 (0) 0 (0)
Diagnosis, n (%)
Idiopathic 3 (38)
Heritable 2 (25)
Connective tissue disease 2 (25)
Drug-toxin induced 1 (13)
WHO functional class, n (%)
I 1 (13)
II 5 (63)
III 2 (25)
IV 0 (0)
Hemodynamics
Right atrial pressure, mm Hg 8 (6, 10)
Mean pulmonary artery pressure, mm Hg 42 (39, 47)
Cardiac output, L/min (thermo) 6 (5, 6)
Pulmonary capillary wedge pressure, mm Hg 11 (9, 11)
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Pulmonary vascular resistance, Wood units (thermo) 5 (4, 6)
PAH therapies, n (%) 
Calcium channel blockers 2 (25)
Phosphodiesterase type 5 inhibitors 6 (75)
Endothelin receptor antagonists 4 (50)
Prostacyclin analogues 4 (50)
sGC 0 (0)
Combination therapy 6 (75)
Data represented as n (%) [where (%) equals column frequency] or median 
(interquartile range). PAH = pulmonary arterial hypertension; BMI=body mass index; 
WHO=World Health Organization; 
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Table 2. Levels of sex hormone, metabolite, and cardiopulmonary markers in healthy controls and pulmonary arterial hypertension 
cases over one menstrual cycle (four study visits).
Visit Healthy Controls PAH Cases
1 Variable Median Q1 – Q3 Min – Max Median Q1 – Q3 Min – Max
Estradiol, pg/mL 33.8 26.6 – 49.9 5.0 – 79.8 47.9 29.1 – 60.9 22.9 – 330.2
DHEA-S, g/dL 190.6 130.3 – 301.9 30.0 – 512.9 59.1 37.0 – 101.4 13.6 – 206.4
16-OHE1, pg/mL 6.0 6.0 – 6.0 6.0 – 181.3 6.0 6.0 – 6.0 6.0 – 6.0
2-ME, pg/mL 7.2 6.0 – 12.2 5.1 – 53.0 8.0 6.0 – 13.7 1.7 – 31.8
6MWD, m 496 384 – 530 320 – 613 429 385 – 499 238 – 586
NT-proBNP, pg/mL 38.1 14.2 – 60.9 5.0 – 287.1 91.8 25.5 – 133.0 11.4 – 317.3 
TAPSE, cm 2.3 2.1 – 2.4 1.7 – 3.0
Healthy Controls PAH Cases
2 Variable Median Q1 – Q3 Min – Max Median Q1 – Q3 Min – Max
Estradiol, pg/mL 64.1 28.5 – 129.0 5.0 – 399.4 85.6 57.4 – 148.4 45.6 – 403.4 
DHEA-S, g/dL 249.6 152.9 – 301.9 32.5 – 483.0 66.0 40.0 – 122.7 34.1 – 206.4
16-OHE1, pg/mL 6.0 6.0 – 6.0 2.1 – 295.9 6.0 6.0 – 6.0 6.0 – 6.0
2-ME, pg/mL 9.6 6.0 – 15.8 4.1 – 41.3 9.8 6.0 – 16.0 6.0 – 22.9
6MWD, m 497 413 – 534 331 – 628 434 379 – 490 263 – 579
NT-proBNP, pg/mL 25 5.4 – 46.1 5.0 – 257.2 50.4 9.9 – 86.4 5.0 – 242.2
TAPSE, cm 2.3 2.1 – 2.5 1.9 – 3.3 
Healthy Controls PAH Cases
3 Variable Median Q1 – Q3 Min – Max Median Q1 – Q3 Min – Max
Estradiol, pg/mL 103.5 35.2 – 186.8 5.0 – 665.1 70.8 58.0 – 105.6 33.4 – 206.4 
DHEA-S, g/dL 237.5 159.2 – 301.9 50.4 – 561.2 56.8 42.9 – 106.7 27.1 – 204.4
16-OHE1, pg/mL 6.0 6.0 – 6.0 2.1 – 267.7 6.0 6.0 – 6.0 6.0 – 7.2 
2-ME, pg/mL 17.1 7.8 – 34.8 3.3 – 73.0 12.3 6.0 – 29.4 5.6 – 36.2 
6MWD, m 491 386 – 516 320 – 624 398 335 – 498 183 – 555
NT-proBNP, pg/mL 26.0 5.9 – 57.4 5.0 – 190.6 75.2 23.3 – 112.2 5.0 – 174.2
TAPSE, cm 2.2 2.0 – 2.5 1.8 – 2.9
Healthy Controls PAH Cases
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4 Variable Median Q1 – Q3 Min – Max Median Q1 – Q3 Min – Max
Estradiol, pg/mL 108.9 20.5 – 145.5 5.0 – 584.1 121.5 84.8 – 151.4 30.6 – 188.7
DHEA-S, g/dL 228.1 167.3 – 278.7 27.7 – 528.5 57.4 43.4 – 77.5 20.9 – 257.2
16-OHE1, pg/mL 6.0 6.0 – 6.0 6.0 – 75.2 6.0 6.0 – 6.0 6.0 – 6.0 
2-ME, pg/mL 13.3 6.0 – 35.9 5.0 – 91.8 12.4 8.9 – 27.7 3.1 – 69.4
6MWD, m 487 410 – 532 319 – 606 428 384 – 478 210 – 566
NT-proBNP, pg/mL 34.1 8.1 – 58.6 5.0 – 172.4 43.8 30.9 – 99.5 5.0 – 290.0
TAPSE, cm 1.9 1.8 – 2.3 1.7 – 2.5 
PAH=pulmonary arterial hypertension; DHEA-S=dehydroepiandrosterone-sulfate; 16-OHE1=16-hydroxyestrone; 
2ME=2methoxyestrone; 6MWD=six-minute walk distance; NT-proBNP=N-terminal pro-brain natriuretic peptide; TAPSE=tricuspid 
annular plane systolic excursion.
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 Figure 1. Hormone fluctuations over the course of the menstrual cycle. Panel A) Mean Ln(estradiol) levels 
over the menstrual cycle (visit 1, 2, 3, and 4) between pulmonary arterial hypertension cases (red) and 
controls (blue) with 95% confidence intervals. Panel B) Mean Ln(DHEA-S) levels over the menstrual cycle 
(visit 1, 2, 3, and 4) between pulmonary arterial hypertension cases (red) and controls (blue) with 95% 
confidence intervals. DHEA-S=dehydroepiandrosterone-sulfate. 
146x48mm (300 x 300 DPI) 
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 Figure 2. Estradiol levels during the menstrual cycle (visit 1, 2, 3, and 4) and the relationship to clinical end 
points in pulmonary arterial hypertension cases (red) and controls (blue) with 95% confidence bands. Panel 
A) Six-minute walk distance (6MWD), meters (m). Panel B) N-terminal prohormone of brain natriuretic 
peptide levels (NT-proBNP), Ln(pg/mL). Panel C) Tricuspid annular plane systolic excursion (TAPSE), 
Ln(centimeters)(cm) in pulmonary arterial hypertension cases only. 
69x132mm (300 x 300 DPI) 
Page 31 of 44
 ANNALSATS Articles in Press. Published September 04, 2020 as 10.1513/AnnalsATS.202006-671OC 
 Copyright © 2020 by the American Thoracic Society 
 Figure 3. Dehydroepiandrosterone-sulfate (DHEA-S) levels and the relationship to clinical end points in 
pulmonary arterial hypertension cases (red) and controls (blue) with 95% confidence bands. Panel A) DHEA-
S levels during the menstrual cycle (visit 1, 2, 3, and 4) and the relationship to six-minute walk distance 
(6MWD), meters (m). Panel B) Overall relationship between DHEA-S and 6MWD, all visits. Panel C) N-
terminal prohormone of brain natriuretic peptide levels (NT-proBNP), Ln(pg/mL). Panel D) Tricuspid annular 
plane systolic excursion (TAPSE), Ln(centimeters)(cm) in pulmonary arterial hypertension cases only. 
146x133mm (300 x 300 DPI) 
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 Figure 4. Relationship between six-minute walk distance (6MWD) by Ln(dehydroepiandrosterone-sulfate) 
(DHEA-S) levels and Ln(2-methoxyestrone) (2-ME) levels in pulmonary arterial hypertension (PAH) cases 
(red cross) and controls (blue pyramids) over time (visits 1,2,3,4); 180O rotation is provided for 
interpretation.   
599x635mm (100 x 100 DPI) 
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Insights from the Menstrual Cycle in Pulmonary Arterial Hypertension 
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Supplemental Data
Sex Hormone and Estradiol Metabolite Levels 
Serum estradiol (E2), dehydoepiandrosterone-sulfate (DHEA-S), luteinizing hormone 
(LH), and testosterone were measured by electrochemiluminescence immunoassay at 
the Laboratory for Clinical Biochemical Research at the University of Vermont (all 
Roche, Indianapolis, IN). The E2 assay has an analytical range of 5 pg/mL – 3000 
pg/mL and coefficients of variation (CVs) of < 6.8%; DHEA-S has detection limits 
between 0.1 – 1000 g/dL and CVs < 8.3%. All CVs for remaining hormones were < 
8.3%. Progesterone was measured by high-pressure liquid chromatography-mass 
spectrometry (LC-MS) (Quest Diagnostics, Chantilly VA and Esoterix, Austin, TX). E2 
metabolites were measured from plasma by LC-MS by the Mass Spectrometry Core at 
the Edinburgh Clinical Research Facility, Queen’s Medical Research Institute in 
Edinburgh, Scotland using previously published methods (1).
  
Markers of Angiogenesis
Extracellular Vesicles
Extracellular vesicles (EVs) were isolated in a series of steps to first remove cells by 
centrifugation (1,900g x 5 minutes at 4°C). The cell-free supernatant was transferred to 
5 ml polypropylene tubes and centrifuged at 5,000g for 10 min at 4°C to remove 
platelets. The supernatant (platelet free plasma) was transferred into a capped 
ultracentrifuge tube and ultracentrifuged at 10,000g for 1 hour to remove cellular debris. 
The supernatant was then ultracentrifuged at 100,000g for 1 hour at 
4°C. Ultracentrifuged pelleted material, containing EVs, was resuspended in 500ul of 
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PBS and 250ul of each sample was added to TRIzol (Invitrogen) for total RNA 
extraction. With the remaining 250 ul, total numbers of EVs were assessed by 
NanoSight utilizing laser illuminated microscopical technique and quantified as EV 
protein (mg/mL). 
MicroRNAs were isolated from EVs in order to gain further insight into specific 
mechanistic pathways linked to sex hormone fluctuations. Total RNA was measured for 
quantity and quality using an Agilent 2100 bioanalyzer. Approximately 0.25 – 0.5% of 
the total RNA fraction extracted were miRNA species. Ten nanograms of total RNA per 
sample, isolated from 5 to 10 µg of EVs, was used to amplify cDNA using the High 
Capacity cDNA transcription kit (Applied Biosystems, all equipment/reagents). cDNA 
pre-amplification reactions were performed using a pooled mixture of all primer assays 
and consisted of one 10 min cycle, 95°C; 14 cycles, 95°C, 15 s; one 4 min cycle, 60°C. 
RT–PCR reactions were performed in with the 7900HT Fast RT PCR System using 
384-well TaqMan® Human MicroRNA Array Cards. The 2−ΔΔCT method was used to 
calculate relative expression of each target miRNA,17 using RNU6B (human array) as 
control.
Vascular Endothelial Growth Factor Receptor 2 and Angiopoietin-2
VEGF-R2 and Angiopoietin (Ang)-2 were measured by electrochemiluminescence at 
the Laboratory for Clinical Biochemical Research at the University of Vermont (Meso 
Scale Diagnostics, Rockville, Maryland). The inter-assay CV for VEGF-R2 was 2.3% 
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and for Ang 2 was 4.1 – 8.4%.
Markers of Cardiopulmonary Function 
Six Minute Walk Test
Weekly six-minute walk tests (6MWTs) were performed according to standardized 
procedures (2). Variability was minimized by administering the test in the same corridor 
for all study visits (and all participants), the avoidance of a “warm-up” period, and using 
standard phrases of encouragement. Intra-class correlation coefficients were 0.95 – 
0.98 from a completed randomized clinical trial in our center (3). 
Diffusing Capacity of the Lung for Carbon Monoxide 
Weekly DLCO measurements were performed by trained staff at the Rhode Island 
Hospital Pulmonary Function Testing (PFT) Laboratory according to standardized 
procedures (4). DLCO was obtained via single-breath method. PFT staff were blinded to 
case-control status and to menstrual phase.
Echocardiography
In PAH cases, echocardiography was performed weekly in accordance with the 
American Society of Echocardiography guidelines (5). Tricuspid annular plane systolic 
excursion (TAPSE) was obtained by aligning an M-mode cursor through the anterior 
tricuspid annulus in the apical 4-chamber view and longitudinal annular displacement 
during systole was recorded. Trained echosonographers were blinded to menstrual 
cycle phase, as was a single reader (author A.P.) who batched all study reads.  
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N-Terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP)
NT-proBNP was measured by electrochemiluminescence at the Laboratory for Clinical 
Biochemical Research at the University of Vermont (Roche, Indianapolis, IN) with a 
detectable range of 5 – 70K pg/mL and CVs of 1.7 – 7.8%.
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Figure E1. 2-methoxyestrone over the course of the menstrual cycle. Mean Ln(2-
methoxyestrone) levels over the menstrual cycle (visit 1, 2, 3, and 4) between 
pulmonary arterial hypertension cases (red) and controls (blue) with 95% confidence 
intervals. 
Figure E2. 2-methoxyestrone levels during the menstrual cycle (visit 1, 2, 3, and 4) and 
the relationship to tricuspid annular plane systolic excursion (TAPSE), 
Ln(centimeters)(cm) in pulmonary arterial hypertension cases only.
Figure E3. Estradiol levels during the menstrual cycle (visit 1, 2, 3, and 4) and the 
relationship to fold changes in microRNA expression in pulmonary arterial hypertension 
cases (red) and controls (blue) with 95% confidence bands. Panel A) microRNA-29c 
expression. Panel B) microRNA-376a expression. Panel C) microRNA-21 expression. 
2−ΔΔCT method was used to calculate relative expression of each target miRNA using 
RNU6B (human array) as control.
Figure E4. Dehydroepiandrosterone-sulfate (DHEA-S) levels during the menstrual cycle 
(visit 1, 2, 3, and 4) and the relationship to fold changes in microRNA expression in 
pulmonary arterial hypertension cases (red) and controls (blue) with 95% confidence 
bands. Panel A) microRNA-29c expression. Panel B) microRNA-376a expression. 
Panel C) microRNA-21 expression. 2−ΔΔCT method was used to calculate relative 
expression of each target miRNA using RNU6B (human array) as control.
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 Figure E1. 2-methoxyestrone over the course of the menstrual cycle. Mean Ln(2-methoxyestrone) levels 
over the menstrual cycle (visit 1, 2, 3, and 4) between pulmonary arterial hypertension cases (red) and 
controls (blue) with 95% confidence intervals. 
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 Figure E2. 2-methoxyestrone levels during the menstrual cycle (visit 1, 2, 3, and 4) and the relationship to 
tricuspid annular plane systolic excursion (TAPSE), Ln(centimeters)(cm) in pulmonary arterial hypertension 
cases only. 
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 Figure E3. Estradiol levels during the menstrual cycle (visit 1, 2, 3, and 4) and the relationship to fold 
changes in microRNA expression in pulmonary arterial hypertension cases (red) and controls (blue) with 
95% confidence bands. Panel A) microRNA-29c expression. Panel B) microRNA-376a expression. Panel C) 
microRNA-21 expression. 2−ΔΔCT method was used to calculate relative expression of each target miRNA 
using RNU6B (human array) as control. 
143x105mm (300 x 300 DPI) 
Page 43 of 44
 ANNALSATS Articles in Press. Published September 04, 2020 as 10.1513/AnnalsATS.202006-671OC 
 Copyright © 2020 by the American Thoracic Society 
 Figure E4. Dehydroepiandrosterone-sulfate (DHEA-S) levels during the menstrual cycle (visit 1, 2, 3, and 4) 
and the relationship to fold changes in microRNA expression in pulmonary arterial hypertension cases (red) 
and controls (blue) with 95% confidence bands. Panel A) microRNA-29c expression. Panel B) microRNA-
376a expression. Panel C) microRNA-21 expression. 2−ΔΔCT method was used to calculate relative 
expression of each target miRNA using RNU6B (human array) as control. 
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